Scholarlink

Aims <p>To describe the main glycemic outcomes and the Quality of Life (QOL) observed in a cohort of people with type 1 (T1D) or type 2 (T2D) insulin-treated diabetes under dialysis who started an Automated Insulin Delivery (AID) system.</p> Methods <p>This is a longitudinal retrospective pilot real-world analysis of 14 individuals with T1D and T2D undergoing dialysis who began using an AID system to optimize glycemic control. All subjects used the MiniMed™ 780G system. Glucose metrics were collected at baseline, 3, 6, and 12 months after initiating the SmartGuard™ feature. The WHOQoL-Bref questionnaire was administered at the last follow-up to evaluate the QOL.</p> Results <p>Out of the 14 people, 8 reached 1-year follow-up. Time in Range (TIR) increased from 63% at baseline to 69% at 12 months, Time Below Range &lt; 70&#xa0;mg/dL (TBR70) decreased from 0.3% to 0%, and Time Above Range &gt; 250&#xa0;mg/dL (TAR250) decreased from 6.7% to 3.9%. Seven out of eight subjects who reached a 12-month follow-up achieved all three glycemic targets for this fragile population (TIR &gt; 50%, TBR70 &lt; 1% and TAR250 &lt; 10%). At the last follow-up, 58.3% of the users were satisfied or very satisfied with their health status, versus only 25% with the previous treatment, and 81.7% had a good or very good QOL, whereas only 8.3% had a good QOL, and no one had a very good QOL with the previous treatment.</p> Conclusion <p>This pilot real-world study showed how the use of an AID system is safe and can help to improve the glycemic outcomes and the QOL of people with diabetes in dialysis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Role of automated insulin delivery (AID) systems in glucose control in patients with diabetes mellitus undergoing dialysis in Calabria: AID-DIAL-CAL

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月15日

查看全文
  • Elena Succurro,
  • Giuseppe Cersosimo,
  • Paola Sarnelli,
  • Francesco Brisinda,
  • Ilaria Gattuso,
  • Valeria Mazza,
  • Giuseppe Fabiano,
  • Fiorella Iorio,
  • Roberta Arena,
  • Giovanni Mazzitello,
  • Ramona Nicotera,
  • Maria Capria,
  • Gianluigi Zaza,
  • Michele Andreucci,
  • Raffaele Mancini,
  • Francesco Andreozzi

摘要

Aims

To describe the main glycemic outcomes and the Quality of Life (QOL) observed in a cohort of people with type 1 (T1D) or type 2 (T2D) insulin-treated diabetes under dialysis who started an Automated Insulin Delivery (AID) system.

Methods

This is a longitudinal retrospective pilot real-world analysis of 14 individuals with T1D and T2D undergoing dialysis who began using an AID system to optimize glycemic control. All subjects used the MiniMed™ 780G system. Glucose metrics were collected at baseline, 3, 6, and 12 months after initiating the SmartGuard™ feature. The WHOQoL-Bref questionnaire was administered at the last follow-up to evaluate the QOL.

Results

Out of the 14 people, 8 reached 1-year follow-up. Time in Range (TIR) increased from 63% at baseline to 69% at 12 months, Time Below Range < 70 mg/dL (TBR70) decreased from 0.3% to 0%, and Time Above Range > 250 mg/dL (TAR250) decreased from 6.7% to 3.9%. Seven out of eight subjects who reached a 12-month follow-up achieved all three glycemic targets for this fragile population (TIR > 50%, TBR70 < 1% and TAR250 < 10%). At the last follow-up, 58.3% of the users were satisfied or very satisfied with their health status, versus only 25% with the previous treatment, and 81.7% had a good or very good QOL, whereas only 8.3% had a good QOL, and no one had a very good QOL with the previous treatment.

Conclusion

This pilot real-world study showed how the use of an AID system is safe and can help to improve the glycemic outcomes and the QOL of people with diabetes in dialysis.